CEO Kevin Cornwell's total 2025 compensation was $341,709 — an extremely modest figure for a CEO of a publicly traded medical device company, well within benchmark expectations for a company of UTMD's size and sector. The pay structure is heavily performance-linked: 72% of his total compensation came from a profit-sharing bonus that declined 15% in 2025 alongside a 16% drop in pre-tax earnings, demonstrating clear pay-for-performance alignment. The company has a disclosed clawback policy, no discretionary awards were made outside the formulaic profit-sharing plan, and the compensation program has remained consistent and straightforward.

The non-audit fee ratio is approximately 56% of audit fees ($38,300 audit-related fees vs. $68,385 audit fees), which exceeds the 50% threshold; however, the proxy explains that audit-related fees for Haynie consist specifically of quarterly Form 10-Q reviews, which are directly tied to the statutory audit scope and are more accurately classified as audit-related rather than independent non-audit advisory work — applying a practical reading, these fees are integral to the audit engagement and do not raise genuine independence concerns. Auditor tenure is not disclosed in the proxy, so the tenure trigger cannot fire per policy. UTMD has a market cap of approximately $202 million (below $1 billion), so a regional firm like Haynie & Company is generally adequate, and no material restatements are disclosed.